Nine-year ocular developmental outcomes after ranibizumab or laser treatment for zone II retinopathy of prematurity: follow-up of a randomized trial cohort.
Yaling Liu, Jiannan Tang, Xinyu Zhao et al.
✦ AI-curated · Sources linked
In 30 seconds
This study followed a randomized trial cohort to assess 9-year ocular developmental outcomes in children treated with intravitreal ranibizumab (IVR) or laser photocoagulation (LP) for zone II retinopathy of prematurity (ROP). The results indicated that visual acuity and refractive outcomes were similar between the two groups, with no significant differences in mean spherical equivalent or best-corrected visual acuity.
Key findings
- Mean spherical equivalent was -1.22 D for LP and -1.90 D for IVR, p = 0.65.
- Best-corrected visual acuity was 0.15 logMAR for LP and 0.21 logMAR for IVR, p = 0.51.
- IVR group had thinner lens thickness (3.52 mm vs. 3.75 mm, p < 0.001).
- Selected electroretinography abnormalities differed between the IVR and LP groups.
Why it matters
Understanding long-term ocular outcomes in children treated for ROP is crucial for guiding treatment decisions. This study provides valuable data on the comparative effectiveness of IVR and LP, although results should be interpreted with caution due to the exploratory nature of some findings.